Actuate Therapeutics Announces Poster Presentations at the 2024 AACR Annual Meeting
April 08, 2024 08:00 ET
|
Actuate Therapeutics
CHICAGO and FORT WORTH, Texas, April 08, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, announced today two poster presentations from...
Actuate Therapeutics Receives FDA Orphan Drug Designation for Elraglusib for Treatment of Pancreatic Cancer
August 01, 2023 08:00 ET
|
Actuate Therapeutics
CHICAGO and FORT WORTH, Texas, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, today announced that the U.S. Food and Drug...
Actuate Therapeutics Announces Poster Presentations at the 2023 ASCO Annual Meeting
May 30, 2023 08:00 ET
|
Actuate Therapeutics
CHICAGO and FORT WORTH, Texas, May 30, 2023 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, announced today four presentations from scientific...
UPDATE -- Actuate Therapeutics Announces Poster Presentations at the 2023 AACR Annual Meeting
April 10, 2023 10:22 ET
|
Actuate Therapeutics
CHICAGO and FORT WORTH, Texas, April 10, 2023 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, announced today three poster presentations from...
Actuate Therapeutics Announces Poster Presentations at the 2023 AACR Annual Meeting
April 10, 2023 07:59 ET
|
Actuate Therapeutics
CHICAGO and FORT WORTH, Texas, April 10, 2023 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, announced today three poster presentations from...
Actuate Therapeutics Congratulates Dr. Patricia LoRusso on Being Named AACR President-Elect
March 23, 2023 10:36 ET
|
Actuate Therapeutics
CHICAGO and FORT WORTH, Texas, March 23, 2023 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc., a Chicago-based clinical-stage biopharmaceutical company advancing lead drug elraglusib (a novel GSK-3...
Drs. Roger B. Cohen, Lee M. Ellis and John L. Marshall Join Actuate Therapeutics’ Scientific Advisory Board
October 18, 2022 07:50 ET
|
Actuate Therapeutics
CHICAGO and FORT WORTH, Texas, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc., a Chicago-based clinical-stage biopharmaceutical company advancing lead drug elraglusib (a novel GSK-3...
Actuate Therapeutics Announces Poster Presentations at the 2022 AACR Annual Meeting
March 28, 2022 07:50 ET
|
Actuate Therapeutics
CHICAGO and FORT WORTH, Texas, March 28, 2022 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, announced today two poster presentations from...
Actuate Therapeutics Announces First Patient Enrolled in Phase 2 Clinical Trial of Elraglusib Plus Retifanlimab as Investigational First Line Therapy for Patients With Advanced Pancreatic Cancer
March 01, 2022 07:55 ET
|
Actuate Therapeutics
CHICAGO and FORT WORTH, Texas, March 01, 2022 (GLOBE NEWSWIRE) -- Actuate Therapeutics and The University of Kansas Cancer Center today announced the enrollment of the first patient on a Phase 2...
Actuate Therapeutics Announces Initiation of a Multicenter Randomized Trial of Elraglusib Plus FOLFIRINOX As First Line Therapy for Advanced Pancreatic Cancer
February 07, 2022 08:50 ET
|
Actuate Therapeutics
CHICAGO and FORT WORTH, Texas, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, today announced the opening of a randomized study...